<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>KRAS G12D protein screening for pancreatic cancer clinical trials using an AlGaN/GaN high electron mobility transistor biosensor - Health AI Hub</title>
    <meta name="description" content="This research paper describes a clinical trial screening for the KRAS G12D protein in pancreatic ductal adenocarcinoma (PDAC) patients and healthy donors using ">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>KRAS G12D protein screening for pancreatic cancer clinical trials using an AlGaN/GaN high electron mobility transistor biosensor</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.10377v1" target="_blank">2512.10377v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-11
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Sheng-Ting Hung, Cheng Yan Lee, Chen-Yu Lien, Cheng-Hsuan Chan, Ya-Han Yang, Quark Yungsung Chen, Kuang-Hung Cheng, Kung-Kai Kuo, Li-Wei Tu, Ching-Wen Chang
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> physics.med-ph
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.10377v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.10377v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This research paper describes a clinical trial screening for the KRAS G12D protein in pancreatic ductal adenocarcinoma (PDAC) patients and healthy donors using an AlGaN/GaN high electron mobility transistor (HEMT) biosensor. The study demonstrated the biosensor's effectiveness by showing that all PDAC patients exhibited significantly higher resistance change ratios compared to healthy controls, indicating its potential for early detection of pancreatic cancer.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer often diagnosed at late stages, leading to poor prognosis. Early detection, particularly through the identification of common mutations like KRAS G12D, is crucial for improving patient outcomes and treatment efficacy.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>Not applicable. The paper focuses on the development and testing of a biosensor technology (AlGaN/GaN HEMT) for direct detection, without mentioning the use of AI for data analysis, diagnosis, or any other application within the scope of the provided abstract.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>A clinical trial screened for the KRAS G12D protein, a common oncogenic mutation, using an AlGaN/GaN HEMT biosensor.</li>
                    
                    <li>The study included 30 pancreatic ductal adenocarcinoma (PDAC) patients and 30 healthy donors.</li>
                    
                    <li>The HEMT biosensor measures changes in electrical resistance upon interaction with the target protein.</li>
                    
                    <li>All PDAC patients displayed resistance change ratios that were higher than the mean plus one standard deviation of the resistance change ratios observed in healthy donors.</li>
                    
                    <li>This distinct separation between patient and healthy donor groups highlights the biosensor's diagnostic capability.</li>
                    
                    <li>The findings suggest the HEMT biosensor is an effective tool for screening KRAS G12D protein.</li>
                    
                    <li>The research indicates a strong potential for the biosensor's application in the early detection of pancreatic cancer.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The study involved a clinical trial screening where an AlGaN/GaN HEMT biosensor was utilized to detect the KRAS G12D protein in samples from 30 PDAC patients and 30 healthy donors. The biosensor's response was quantified by measuring changes in electrical resistance, and these resistance change ratios were then compared between the two groups.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The primary finding was that all 30 PDAC patients exhibited resistance change ratios significantly higher than those obtained from the healthy donors. Specifically, every PDAC patient's resistance change ratio exceeded the mean resistance change ratio of healthy donors by more than one standard deviation, demonstrating a clear diagnostic distinction.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This research introduces a novel, effective biosensor technology that could revolutionize early detection strategies for pancreatic cancer, particularly for KRAS G12D-positive cases. Its successful application in differentiating PDAC patients from healthy individuals suggests the potential for a new, sensitive, and rapid diagnostic tool that could enable earlier intervention and potentially improve survival rates for a highly lethal disease.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state limitations, but common considerations for such preliminary clinical trial screenings often include the relatively small sample size (30 patients/30 healthy donors), the need for further validation in larger and more diverse cohorts, detailed assessment of specificity and sensitivity, and exploration of potential interfering factors in clinical samples.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>While not explicitly stated as 'future directions' in the abstract, the phrase 'reveal its potential for early detection' implies further research is warranted. This would likely include expanding the study to a larger cohort, conducting multi-center trials for validation, assessing the biosensor's performance characteristics (e.g., sensitivity, specificity, positive/negative predictive values), and potentially exploring its application for monitoring disease progression or treatment response.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Gastroenterology</span>
                    
                    <span class="tag">Medical Diagnostics</span>
                    
                    <span class="tag">Biomarker Detection</span>
                    
                    <span class="tag">Personalized Medicine</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">KRAS G12D</span>
                    
                    <span class="tag tag-keyword">Pancreatic Cancer</span>
                    
                    <span class="tag tag-keyword">PDAC</span>
                    
                    <span class="tag tag-keyword">HEMT biosensor</span>
                    
                    <span class="tag tag-keyword">AlGaN/GaN</span>
                    
                    <span class="tag tag-keyword">Early Detection</span>
                    
                    <span class="tag tag-keyword">Biomarker Screening</span>
                    
                    <span class="tag tag-keyword">Oncology</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Clinical trials screening KRAS G12D protein for 30 pancreatic ductal adenocarcinoma (PDAC) patients and 30 healthy donors were conducted utilizing an AlGaN/GaN high electron mobility transistor (HEMT) biosensor. All resistance change ratios of PDAC patients are higher than the standard deviation above the mean resistance change ratio obtained from all healthy donors. The results demonstrate the effectiveness of the HEMT biosensor and reveal its potential for early detection of pancreatic cancer with KRAS G12D protein screening.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>